Unbuckling lipodystrophy from insulin resistance and hypertension

被引：18

作者：

Hegele, RA

Leff, T

机构：

[1] Robarts Res Inst, Blackburn Cardiovasc Genet Lab, London, England

[2] Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2004年 / 114卷 / 02期

关键词：

D O I：

10.1172/JCI200422382

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Lipodystrophy and insulin resistance are the core features of human PPARgamma deficiency states. Metabolic complications in PPARgamma deficiency, such as hypertension, have been considered to be secondary to insulin resistance. However, a new mouse model that expresses the analog of a human PPARG mutation displays minimal lipodystrophy and insulin resistance but rather severe hypertension (see the related article beginning on page 240). Furthermore, the mutant protein appears to directly modulate the renin-angiotensin system in adipose tissue, providing evidence of the pleiotropic effects of PPARgamma.

引用

页码：163 / 165

页数：3

共 16 条

[1] A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy
Agarwal, AK
Garg, A
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) : 408 - 411
[2] Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension
Barroso, I
Gurnell, M
Crowley, VEF
Agostini, M
Schwabe, JW
Soos, MA
Maslen, GL
Williams, TDM
Lewis, H
Schafer, AJ
Chatterjee, VKK
O'Rahilly, S
[J]. NATURE, 1999, 402 (6764) : 880 - 883
[3] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Cleeman, JI
Grundy, SM
Becker, D
Clark, LT
Cooper, RS
Denke, MA
Howard, WJ
Hunninghake, DB
Illingworth, DR
Luepker, RV
McBride, P
McKenney, JM
Pasternak, RC
Stone, NJ
Van Horn, L
Brewer, HB
Ernst, ND
Gordon, D
Levy, D
Rifkind, B
Rossouw, JE
Savage, P
Haffner, SM
Orloff, DG
Proschan, MA
Schwartz, JS
Sempos, CT
Shero, ST
Murray, EZ
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
[4] Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity
Dobrian, AD
Schriver, SD
Khraibi, AA
Prewitt, RL
[J]. HYPERTENSION, 2004, 43 (01) : 48 - 56
[5] The adipose-tissue renin-angiotensin-aldosterone system:: role in the metabolic syndrome?
Engeli, S
Schling, P
Gorzelniak, K
Boschmann, M
Janke, E
Ailhaud, G
Teboul, M
Massiéra, F
Sharma, AA
[J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (06) : 807 - 825
[6] Phenomics, lipodystrophy, and the metabolic syndrome
Hegele, RA
[J]. TRENDS IN CARDIOVASCULAR MEDICINE, 2004, 14 (04) : 133 - 137
[7] Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy
Hegele, RA
Kraw, ME
Ban, MR
Miskie, BA
Huff, MW
Cao, HN
[J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (01) : 111 - 116
[8] Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome
Hegele, RA
[J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2003, 14 (08) : 371 - 377
[9] PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy
Hegele, RA
Cao, HN
Frankowski, C
Mathews, ST
Leff, T
[J]. DIABETES, 2002, 51 (12) : 3586 - 3590
[10] Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study
Laaksonen, DE
Lakka, HM
Niskanen, LK
Kaplan, GA
Salonen, JT
Lakka, TA
[J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 156 (11) : 1070 - 1077

← 1 2 →